Pilgrim's Pride ( PPC) downgraded at B Riley Caris from buy to neutral, B Riley Caris asid. Valuation call, based on a $9 price target. Ross Stores ( ROST) upgraded at Credit Suisse from neutral to outperform, Credit Suisse said. $68 price target. Company should continue to benefit from a favorable operating environment. Sandisk ( SNDK) upgraded at Needham from hold to buy, Needham said. $60 price target. Company is realizing higher margins. Splunk ( SPLK) rated new outperform at BMO. $39 price target. Company should be able to capture more large enterprise deals. Symantec ( SYMC) downgraded at Wunderlich from buy to hold, Wunderlich said. $22 price target. Company's strategic turnaround will take time. Symantec downgraded at Stifel from Buy to Hold, Stifel Nicolaus said. Valuation call, as the company lacks near-term catalysts. Tiffany ( TIF) downgraded at Canaccord from Buy to Hold, Canaccord Genuity said. $58 price target. Sales momentum continues to decelerate in an uncertain economy. Veeco Instruments ( VECO) downgraded at UBS to Neutral from Buy, UBS said. $34 price target. China MOCVD demand likely remains lower than expected.
STOCK COMMENTS / EPS CHANGES
Apple ( AAPL) numbers lowered at Oppenheimer. Shares of AAPL now seen reaching $600, Oppenheimer said. Estimates also lowered on disappointing guidance. Outperform rating. Apple estimates, target reduced at BMO. AAPL estimates were cut through 2014, BMO Capital said. Company lowered its guidance. Outperform rating and new $580 price target. Apple numbers cut at UBS. Shares of AAPL now seen reaching $600, UBS said. Estimates also lowered on mediocre outlook. Buy rating. Apple estimates, target cut at Sterne Agee. Shares of AAPL now seen reaching $715, according to Sterne Agee. Estimates also reduced, given the company's new guidance. Buy rating. Apple numbers cut at Citigroup. Shares of AAPL now seen reaching $500, Citigroup said. Estimates also lowered on weaker iPhone shipments. Neutral rating. Abbvie ( ABBV) estimates, target boosted at BMO. Shares of ABBV now seen reaching $41, according to BMO Capital. Estimates also upped, given highrer Humira growth. Outperform rating. Amgen ( AMGN) target raised at Bernstein to $101, Bernstein said. Solid quarter, but lacking near term catalysts. Market Perform rating. Baker Hughes ( BHI) numbers cut at BMO. Shares of BHI now seen reaching $43, BMO Capital Markets said. Estimates also lowered on outlook which lacks sense of urgency. Market Perform rating. Baker Hughes target raised at Jefferies to $48, Jefferies said. DCF mechanics. Hold rating.